MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218).


Journal

European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 16 01 2020
accepted: 23 07 2020
revised: 18 06 2020
pubmed: 28 8 2020
medline: 15 4 2021
entrez: 28 8 2020
Statut: ppublish

Résumé

Radiomic involves testing the associations of a large number of quantitative imaging features with clinical characteristics. Our aim was to extract a radiomic signature from axial T2-weighted (T2-W) magnetic resonance imaging (MRI) of the whole prostate able to predict oncological and radiological scores in prostate cancer (PCa). This study included 65 patients with localized PCa treated with radiotherapy (RT) between 2014 and 2018. For each patient, the T2-W MRI images were normalized with the histogram intensity scale standardization method. Features were extracted with the IBEX software. The association of each radiomic feature with risk class, T-stage, Gleason score (GS), extracapsular extension (ECE) score, and Prostate Imaging Reporting and Data System (PI-RADS v2) score was assessed by univariate and multivariate analysis. Forty-nine out of 65 patients were eligible. Among the 1702 features extracted, 3 to 6 features with the highest predictive power were selected for each outcome. This analysis showed that texture features were the most predictive for GS, PI-RADS v2 score, and risk class; intensity features were highly associated with T-stage, ECE score, and risk class, with areas under the receiver operating characteristic curve (ROC AUC) ranging from 0.74 to 0.94. MRI-based radiomics is a promising tool for prediction of PCa characteristics. Although a significant association was found between the selected features and all the mentioned clinical/radiological scores, further validations on larger cohorts are needed before these findings can be applied in the clinical practice. • A radiomic model was used to classify PCa aggressiveness. • Radiomic analysis was performed on T2-W magnetic resonance images of the whole prostate gland. • The most predictive features belong to the texture (57%) and intensity (43%) domains.

Identifiants

pubmed: 32852590
doi: 10.1007/s00330-020-07105-z
pii: 10.1007/s00330-020-07105-z
doi:

Types de publication

Clinical Trial, Phase II Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

716-728

Références

Donovan JL, Hamdy FC, Lane JA et al (2016) Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 375(15):1425–1437
doi: 10.1056/NEJMoa1606221
National Comprehensive Cancer Network (NCCN). Prostate cancer. In: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, version 2.2019-April 24, 2019. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx Accessed: May 28, 2019
Morgans (2018) Optimization of risk stratification in localized prostate cancer. J Clin Oncol 36(6):528–533
doi: 10.1200/JCO.2017.76.2971
Ahmed HU, Bosaily AE-S, Brown LC et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389(10071):815–822
doi: 10.1016/S0140-6736(16)32401-1
Ma S, Xie H, Wang H et al (2019) MRI-based radiomics signature for the preoperative prediction of extracapsular extension of prostate cancer. J Magn Reson Imaging. 50(6):1914–1925
Aerts HJ, Velazquez ER, Leijenaar RT et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun:1–8
Nketiah G, Elschot M, Kim E et al (2017) T2-weighted MRI-derived textural features reflect prostate cancer aggressiveness: preliminary results. Eur Radiol 27:3050–3059
doi: 10.1007/s00330-016-4663-1
Wibmer A, Hricak H, Gondo T et al (2015) Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores. Eur Radiol 25:2840–2850
doi: 10.1007/s00330-015-3701-8
Barentsz JO, Richenberg J, Clements R et al (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22(4):746–757
doi: 10.1007/s00330-011-2377-y
Timon G, Ciardo D, Bazani A et al (2018) Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218. Br J Radiol. 91(1089):20160725
Zhang L, Fried DV, Fave XJ, Hunter LA, Yang J, Court LE (2015) IBEX: an open infrastructure software platform to facilitate collaborative work in radiomics. Med Phys 42(3):1341–1353
doi: 10.1118/1.4908210
Nyul LG, Udupa JK (1999) On standardizing the MR image intensity scale. Magn Reson Med 42:072–1081
doi: 10.1002/(SICI)1522-2594(199912)42:6<1072::AID-MRM11>3.0.CO;2-M
Madabhushi A, Udupa JK, Souza A (2006) Generalized scale: theory, algorithms, and application to image inhomogeneity correction. Comput Vis Image Underst 101(2):100–121
doi: 10.1016/j.cviu.2005.07.010
Madabhushi A, Udupa JK (2006) New methods of mr image intensity standardization via generalized scale. Med Phys 33(9):3426–3434
doi: 10.1118/1.2335487
Isaksson LJ, Raimondi S, Botta F et al (2020) Effects of MRI image normalization techniques in prostate cancer radiomics. Phys Med 71:7–13
doi: 10.1016/j.ejmp.2020.02.007
Perneger TV (1999) Adjusting for multiple testing in studies is less important than other concerns. BMJ 318(7193):1288
doi: 10.1136/bmj.318.7193.1288a
Luzzago S, Petralia G, Musi G et al (2019) Multiparametric magnetic resonance imaging second opinion may reduce the number of unnecessary prostate biopsies: time to improve radiologists’ training program? Clin Genitourin Cancer 17(2):88–96
doi: 10.1016/j.clgc.2018.10.006
Sonn GA, Fan RE, Ghanouni P et al (2017) Prostate magnetic resonance imaging interpretation varies substantially across radiologists. Eur Urol Focus. 5(4):592–599
Hectors SJ, Cherny M, Yadav KK et al (2019) Radiomics features measured with multiparametric magnetic resonance imaging predict prostate cancer aggressiveness. J Urol. 02(3):498–505
Cuocolo R, Stanzione A, Ponsiglione A et al (2019) Clinically significant prostate cancer detection on MRI: a radiomic shape features study. Eur J Radiol 116:144–149
doi: 10.1016/j.ejrad.2019.05.006
Schwier M, van Griethuysen J, Vangel MG et al (2019) Repeatability of multiparametric prostate MRI radiomics features. Sci Rep 9(1):9441
doi: 10.1038/s41598-019-45766-z
Bianchini L, Botta F, Origgi D et al (2020) PETER PHAN: an MRI phantom for the optimisation of radiomic studies of the female pelvis. Phys Med 71:71–81
doi: 10.1016/j.ejmp.2020.02.003
Fehr D, Veeraraghavan H, Wibmer A et al (2015) Automatic classification of prostate cancer Gleason scores from multiparametric magnetic resonance images. Proc Natl Acad Sci U S A 112(46):E6265–E6273
doi: 10.1073/pnas.1505935112
Chaddad A, Niazi T, Probst S, Bladou F, Anidjar M, Bahoric B (2018) Predicting Gleason score of prostate cancer patients using radiomic analysis. Front Oncol 8
Abdollahi H, Mofid B, Shiri I et al (2019) Machine learning-based radiomic models to predict intensity-modulated radiation therapy response, Gleason score and stage in prostate cancer. Radiol Med. 124(6):555–567
Wang J, Wu CJ, Bao ML, Zhang J, Wang XN, Zhang YD (2017) Machine learning-based analysis of MR radiomics can help to improve the diagnostic performance of PI-RADS v2 in clinically relevant prostate cancer. Eur Radiol 27(10):4082–4090
doi: 10.1007/s00330-017-4800-5
Algohary A, Viswanath S, Shiradkar R et al (2018) Radiomic features on MRI enable risk categorization of prostate cancer patients on active surveillance: preliminary findings. J Magn Reson Imaging 48(3):818–828
doi: 10.1002/jmri.25983
Tanadini-Lang S, Bogowicz M, Veit-Haibach P et al (2018) Exploratory radiomics in computed tomography perfusion of prostate cancer. Anticancer Res 38(2):685–690
pubmed: 29374691
Brooks FJ, Grigsby PW (2014) The effect of small tumor volumes on studies of intratumoral heterogeneity of tracer uptake. J Nucl Med 55(1):37–42
doi: 10.2967/jnumed.112.116715
Oommen T, Baise LG, Vogel RM (2011) Sampling bias and class imbalance in maximum-likelihood logistic regression. Math Geosci 43(1):99–120
doi: 10.1007/s11004-010-9311-8
Kasivisvanathan V, Rannikko AS, Borghi M et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378(19):1767–1777
doi: 10.1056/NEJMoa1801993
Gao J, Jiang Q, Zhou B, Chen D (2019) Convolutional neural networks for computer-aided detection or diagnosis in medical image analysis: an overview. Math Biosci Eng 16(6):6536
doi: 10.3934/mbe.2019326

Auteurs

Simone Giovanni Gugliandolo (SG)

Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Matteo Pepa (M)

Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Lars Johannes Isaksson (LJ)

Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
European School of Molecular Medicine, IFOM-IEO Campus, Via Adamello, 16, 20139, Milan, Italy.

Giulia Marvaso (G)

Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy. Giulia.Marvaso@ieo.it.
Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy. Giulia.Marvaso@ieo.it.

Sara Raimondi (S)

Molecular and Pharmaco-Epidemiology Unit, Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Francesca Botta (F)

Medical Physics Unit, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Sara Gandini (S)

Molecular and Pharmaco-Epidemiology Unit, Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Delia Ciardo (D)

Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Stefania Volpe (S)

Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy.

Giulia Riva (G)

Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.

Damari Patricia Rojas (DP)

Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Dario Zerini (D)

Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Paola Pricolo (P)

Division of Radiology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Sarah Alessi (S)

Division of Radiology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Giuseppe Petralia (G)

Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy.
Division of Radiology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Paul Eugene Summers (PE)

Division of Radiology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Frnacesco Alessandro Mistretta (FA)

Division of Urology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy.

Stefano Luzzago (S)

Division of Urology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Federica Cattani (F)

Medical Physics Unit, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Ottavio De Cobelli (O)

Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy.
Division of Urology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Enrico Cassano (E)

Breast Imaging Division, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Marta Cremonesi (M)

Radiation Research Unit, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Massimo Bellomi (M)

Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy.
Division of Radiology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Roberto Orecchia (R)

Scientific Directorate, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Barbara Alicja Jereczek-Fossa (BA)

Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH